Gross profit for the third quarter of 2025 was $24.2 million or 80% of revenue, a decrease of $1.0 million compared to gross profit of $25.2 million or 71% of revenue for the third quarter of 2024.

The live webcasts and archives of these fireside chats can also be accessed on the “ News & Events ” page in the Investor Relations section of the Mineralys Therapeutics website.

Conference Call and Webcast scheduled for tomorrow, November 6, 2025 at 10:00 am MT. EAGLE, Idaho, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the pa ...

Research and development expenses were $6.1 million for the three months ended September 30, 2025, as compared to $8.8 million for the three months ended September 30, 2024. The decrease of $2.6 ...

GAAP net loss for the third quarter of 2025 was $38.0 million, compared to $60.7 million for the third quarter of 2024. Non-GAAP net loss for the third quarter of 2025 was $36.8 million, compared to ...

Cytek will host a conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference ...

Adaptive Biotechnologies will host a conference call to discuss its third quarter 2025 financial results after market close on Wednesday, November 5, 2025 at 4:30 PM Eastern Time. The conference call ...

BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its ...

Guggenheim Securities Inaugural Healthcare Innovation Conference: a corporate presentation will take place on Monday, November 10, 2025, at 9:30am ET at the InterContinental Boston in Boston, MA. A ...

HealthEquity and its subsidiaries administer HSAs and various other consumer-directed benefits for over 17 million accounts, working in close partnership with employers, benefits advisors, and health ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...